Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial save search
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Alliance Data Systems Corporation n/k/a Bread Financial Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - LYLT, LYLTQ
Published: 2023-06-05 (Crawled : 00:00) - prnewswire.com
HBNC | $12.26 1.66% 1.63% 150K
|
Finance
|
| O: -0.42%
H: 10.17%
C: 7.76%
trusted corporation deadline trial financial
Global Internet of People, Inc. Selected as a Cooperating Institutional Partner to the Luolong District Industrial Development Think Tank in Luoyang City, China
Published: 2022-02-25 (Crawled : 14:00) - globenewswire.com
SDH | $3.38 51.57% -5.09%
|
|
| O: 0.0%
H: 0.0%
C: -2.33%
internet trial china
Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites
Published: 2021-10-27 (Crawled : 14:00) - biospace.com/
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
|
| O: -1.2%
H: 2.85%
C: -2.03%
adhd
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
Published: 2022-06-16 (Crawled : 13:00) - biospace.com/
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
|
| O: -4.85%
H: 4.08%
C: -1.86%
vitargus biopharma australia
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
Published: 2023-02-23 (Crawled : 22:00) - globenewswire.com
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
|
| O: -1.38%
H: 0.69%
C: -3.47%
biopharma trials
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
Published: 2022-05-10 (Crawled : 13:20) - biospace.com/
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
|
| O: 2.0%
H: 9.19%
C: 6.11%
biopharma adhd
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
|
| O: 0.87%
H: 2.16%
C: 2.16%
biopharma adhd enroll
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study
Published: 2022-02-02 (Crawled : 14:00) - biospace.com/
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
|
| O: 0.39%
H: 0.0%
C: 0.0%
biopharma ces adhd
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
Published: 2022-06-01 (Crawled : 22:00) - biospace.com/
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
|
| O: -1.01%
H: 4.59%
C: 3.32%
biopharma adhd
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials
Published: 2023-12-05 (Crawled : 13:30) - globenewswire.com
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
|
| O: 5.07%
H: 1.38%
C: -0.69%
irwin cancer depression biopharma trials medical
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial
Published: 2021-07-23 (Crawled : 21:00) - globenewswire.com
PTIX 4 | $1.57 25.6% 19.35% 71K
|
Administrative and Support and ...
| Email alert
Add to watchlist
trial enroll
Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease
Published: 2022-10-17 (Crawled : 15:00) - biospace.com/
KPRX | $0.5795 19.49% 19.3% 680K
|
Manufacturing
|
| O: 4.71%
H: 0.0%
C: -4.5%
kio-100 treatment pharmaceuticals disease ocular trial publication phase 1
Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End
Published: 2022-11-09 (Crawled : 17:00) - biospace.com/
KPRX | $0.5795 19.49% 19.3% 680K
|
Manufacturing
|
| O: -1.92%
H: 2.45%
C: -3.92%
kio-301 pharmaceuticals trial financial phase 1
Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa
Published: 2022-06-27 (Crawled : 14:00) - biospace.com/
KPRX | $0.5795 19.49% 19.3% 680K
|
Manufacturing
|
| O: 3.12%
H: 0.0%
C: -3.05%
kio-301 trial approval
Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects
Published: 2023-04-26 (Crawled : 14:00) - biospace.com/
KPRX | $0.5795 19.49% 19.3% 680K
|
Manufacturing
|
| O: 2.09%
H: 9.33%
C: 4.78%
kio-201 trial phase 2
Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases
Published: 2023-04-17 (Crawled : 15:00) - biospace.com/
KPRX | $0.5795 19.49% 19.3% 680K
|
Manufacturing
|
| O: -1.25%
H: 0.0%
C: -1.22%
kio-101 ocular presentation treatment pharmaceuticals trial phase 2
Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023
Published: 2023-01-03 (Crawled : 17:00) - biospace.com/
KPRX | $0.5795 19.49% 19.3% 680K
|
Manufacturing
|
| O: 1.17%
H: 20.17%
C: -2.31%
kio-201 pharmaceuticals expected trial
Groundbreaking clinical trial underway to improve vision in individuals with advanced Retinitis Pigmentosa (RP)
Published: 2023-02-14 (Crawled : 00:00) - biospace.com/
KPRX | $0.5795 19.49% 19.3% 680K
|
Manufacturing
|
| O: -1.21%
H: 0.0%
C: -16.95%
trial
Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022
Published: 2022-04-25 (Crawled : 15:00) - biospace.com/
KPRX | $0.5795 19.49% 19.3% 680K
|
Manufacturing
|
| O: 5.79%
H: 0.0%
C: -8.46%
kio-101 trial presentation
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Published: 2024-03-28 (Crawled : 16:00) - biospace.com/
KPRX | $0.5795 19.49% 19.3% 680K
|
Manufacturing
|
| O: -2.26%
H: 20.0%
C: 17.67%
pharmaceuticals meeting trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.